Kv7.2 (KCNQ2) Protein

Kv7.2 (KCNQ2) Protein

Kv7.2 (KCNQ2) Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Kv7.2 (KCNQ2) Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Kv7.2 (KCNQ2)</td>
</tr>
<tr>
<td class="label">Gene Encoding</td>
<td>KCNQ2</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O43526</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~100 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Axon initial segment, soma, dendrites</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Voltage-gated potassium channels (Kv7/KCNQ)</td>
</tr>
<tr>
<td class="label">Channel Stoichiometry</td>
<td>Tetramer (usually Kv7.2/7.3 heterotetramers)</td>
</tr>
</table>

Introduction

Kv7.2 (Kcnq2) Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Kv7.2 (KCNQ2) is a voltage-gated potassium channel that mediates the M-current, a slowly activating potassium current critical for neuronal excitability regulation. Kv7.2 channels stabilize the resting membrane potential and prevent excessive neuronal firing. Mutations in KCNQ2 cause neonatal seizures and epileptic encephalopathy. [@retigabine2012]

...

Kv7.2 (KCNQ2) Protein

Kv7.2 (KCNQ2) Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Kv7.2 (KCNQ2) Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Kv7.2 (KCNQ2)</td>
</tr>
<tr>
<td class="label">Gene Encoding</td>
<td>KCNQ2</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O43526</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~100 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Axon initial segment, soma, dendrites</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Voltage-gated potassium channels (Kv7/KCNQ)</td>
</tr>
<tr>
<td class="label">Channel Stoichiometry</td>
<td>Tetramer (usually Kv7.2/7.3 heterotetramers)</td>
</tr>
</table>

Introduction

Kv7.2 (Kcnq2) Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Kv7.2 (KCNQ2) is a voltage-gated potassium channel that mediates the M-current, a slowly activating potassium current critical for neuronal excitability regulation. Kv7.2 channels stabilize the resting membrane potential and prevent excessive neuronal firing. Mutations in KCNQ2 cause neonatal seizures and epileptic encephalopathy. [@retigabine2012]

This protein is involved in:

• M-current: Mediates slowly activating potassium current
• Neuronal excitability: Stabilizes resting membrane potential
• Seizure suppression: Prevents hyperexcitability
• Disease associations: Benign familial neonatal seizures, epileptic encephalopathy, migraine

Kv7.2 (encoded by KCNQ2) is the founding member of the KCNQ (Kv7) family of voltage-gated potassium channels. Together with Kv7.3, it forms the neuronal M-current, a critical regulator of neuronal excitability.

Protein Overview

Structure

Kv7.2 contains six transmembrane segments:

• S1-S4: Voltage-sensing domain (S4 carries positive charges)
• S5-S6: Pore domain (selectivity filter: GYG)
• S6: Gate region controlling opening/closing
• N-terminus: Assembly domain
• C-terminus: Calmodulin-binding domain, assembly domain

Heteromeric Assembly

• Kv7.2/7.3: Primary native channel composition
• Co-assembly required: For functional M-current
• Calmodulin interaction: Essential for proper trafficking

Normal Function

M-Current Properties

• Slow activation: Time constant ~100 ms
• Slow deactivation: Time constant ~300 ms
• Voltage range: Activates at -50 to -30 mV
• Non-inactivating: Sustained current during depolarization

Physiological Roles

• Neuronal excitability: Determines firing threshold and pattern
• Subthreshold integration: Modulates response to EPSPs
• Spike frequency adaptation: Controls firing rate
• Axon initial segment: Regulates action potential initiation
• Neuroprotection: Reduces excitotoxicity risk

Regulation

• Neuronal activity: Activity-dependent modulation
• Phosphorylation: PKC, PKA modulation
• Ankyrin-G: Anchored at axon initial segment
• Calmodulin: Ca2+-dependent regulation

Role in Disease

Benign Familial Neonatal Seizures (BFNS1)

• Autosomal dominant: 50% chance of inheritance
• Channel dysfunction: Dominant-negative effect
• Benign prognosis: Seizures resolve by age 1-4
• Normal development: Typically typical outcome

Early-Onset Epileptic Encephalopathies

• De novo mutations: Cause severe phenotypes
• Ohtahara syndrome: Early infantile epileptic encephalopathy
• West syndrome: Infantile spasms
• Spectrum: Variable severity based on mutation

Alzheimer's Disease

• Therapeutic potential: M-current enhancers
• Retigabine: FDA-approved anticonvulsant activates Kv7.2/7.3
• Neuroprotection: Reduces [amyloid-beta](/proteins/amyloid-beta) toxicity
• Cognitive effects: Being investigated

Neuropathic Pain

• Peripheral hyperexcitability: GIRK-like effects
• Drug target: Kv7 activators for pain relief

Therapeutic Targeting

Approved Drugs

• Retigabine (Azilect): Kv7.2/7.3 activator (withdrawn from market)
• Flupirtine: Kv7 activator, analgesic

Investigational

• Kv7.2/7.3 agonists: For AD, neuropathic pain
• Channel blockers: For seizure control
• Gene therapy: Under development

Key Publications

M-current discovery and characterization (1980). Nature. PMID: 6255612(https://pubmed.ncbi.nlm.nih.gov/6255612/)

KCNQ2 mutations in neonatal seizures (2012). Brain. PMID: 22427328(https://pubmed.ncbi.nlm.nih.gov/22427328/)

Kv7 channels in neuropathic pain (2019). Nature Reviews Drug Discovery. PMID: 31110317(https://pubmed.ncbi.nlm.nih.gov/31110317/)

Kv7.2/7.3 in Alzheimer's disease (2021). Journal of Neuroscience. PMID: 33883218(https://pubmed.ncbi.nlm.nih.gov/33883218/)

See Also

• [KCNQ2 Gene](/proteins/kcnq2-protein)
• [KCNQ3 Gene](/proteins/kcnq3-protein)
• [Potassium Channels](/entities/potassium-channels)
• [Neuronal Excitability](/mechanisms/neuronal-excitability-pathway)
• [Excitotoxicity](/mechanisms/excitotoxicity-pathway)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction-pathway)

External Links

• [UniProt: Kv7.2](https://www.uniprot.org/uniprot/O43526)
• [IUPHAR: Kv7 Channels](https://www.guidetopharmacology.org/GRID/FamilyIntroduction?familiar=&topfamily=Voltage-gated%20potassium%20channels&subfamily=Kv7%20%28KCNQ%29%20channels)
• [PDB: Kv7 Structures](https://www.rcsb.org/search?searchTerm=kv7%20kcnq)

Background

The study of Kv7.2 (Kcnq2) Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• [Allen Human Brain Atlas - Gene Expression](https://human.brain-map.org/microarray/search/show?search_term=KCNQ2)
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/)

Molecular Mechanisms

Channel Structure

• KCNQ2 encodes the voltage-gated potassium channel subunit
• Forms homomers or heteromers with KCNQ3
• M-channel regulates neuronal excitability

Neuronal Function

• Controls resting membrane potential
• Regulates action potential repolarization
• Modulates neurotransmitter release

Therapeutic Targeting

• Retigabine: FDA-approved M-channel opener (ezogabine)
• Flupirtine: Analgesic with M-channel activating properties
• Novel compounds: Under development for epilepsy and pain

Disease Mechanisms

Epilepsy

• Loss-of-function mutations cause benign familial neonatal seizures
• Reduced M-current leads to hyperexcitability
• Target for anti-epileptic drugs

Neuroprotection

• M-channel activation reduces excitotoxicity
• Potential for AD and PD neuroprotection
• Reduces calcium influx via NMDA receptors

Research Directions

• Novel M-channel modulators for neurological disorders
• Understanding KCNQ2 mutations in neonatal epilepsy
• Therapeutic applications in excitotoxicity

See Also

• [KCNQ2 Gene](/genes/kcnq2)
• [Ion Channels in Neurodegeneration](/diseases/neurodegeneration)
• [Epilepsy](/diseases/epilepsy)

External Links

• [NCBI - KCNQ2](https://www.ncbi.nlm.nih.gov/gene/3785)
• [UniProt - Kv7.2](https://www.uniprot.org/uniprot/O43525)

References

[Unknown, KCNQ2/3 potassium channels in neuronal excitability (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15537883/)

[Unknown, Retigabine for KCNQ-related epilepsy (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22366792/)